login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Clinical vs. anatomical risk stratification following complex PCI


Friday, 05 Aug 2011 10:27
Ralf Lehmann
Ralf Lehmann


By Ralf Lehmann


Surgical or interventional coronary revascularisation is the primary therapeutic choice in coronary artery disease patients with multivessel disease or with involvement of the left main coronary artery (LMCA). The decision between revascularisation by percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) in multivessel disease patients is often made by estimating the perioperative mortality for CABG using logistic regression-based clinical risk scores such as the EuroSCORE. However, the EuroSCORE is not validated regarding long-term outcome after CABG. The SYNTAX Score represents an anatomical risk stratification score for coronary artery disease patients and has recently been proposed to predict clinical outcome after multivessel PCI. However, the prognostic impact of different clinical and anatomical risk stratification scores for the long-term survival after multivessel PCI has not yet been investigated and compared sufficient. Finally, current guidelines on choosing a revascularisation strategy only focus on anatomical features rather than on clinical parameters.

 

In order to investigate these questions we conducted a single-centre registry with “all-comers” patients. Our study population consisted of 740 consecutive patients undergoing coronary stent implantation in at least two main vessel territories (LAD, RCA, RCX, RIM, LMCA=counted as two territories) in a single session at the University Hospital of Frankfurt, Germany. Clinical long-term follow-up regarding survival was available in a total of 726 (98%) patients with a mean follow-up of 5.3±2.1 years (patients alive).

 

Nearly half of the patients received multivessel PCI in the setting of an acute coronary syndrome (n=150 NSTEMI; n=191 STEMI). The mean age was 65±11 years, 77% were male, and 29% of the patients were diabetic. By definition the EuroSCORE was markedly lower for stable patients in comparison to patients with an acute coronary syndrome (stable 4.1±4.5, NSTEMI 13.9±13.3, STEMI 18.1±18.7, p <0.001). However, for the SYNTAX Score this difference was much less pronounced but still significant (stable coronary artery disease 14.9±8.6; NSTEMI 17.8±9.9; STEMI 18.3±9.0: p <0.001).

The patient population was divided into tertiles for each of the calculated scores.

 

Subsequently Kaplan-Meier survival estimates were performed to compare the different risk levels. Patients in the higher EuroSCORE tertile experienced a dramatically elevated mortality risk across the entire study period when compared with the lower two tertiles. The elevated mortality rate in the highest tertiles of the clinical scores was attributed in part to the high short-term mortality of patients with acute myocardial infarction and especially cardiogenic shock. This led us to perform a separate analysis for stable patients only, in which the discrimination of the long-term survival by tertiles of EuroSCORE was even more pronounced, as reflected by the diverging Kaplan-Meier curves. These results indicate that the discriminating potential of the clinical scores is not only powered by short term “acute” clinical parameters. Finally, the SYNTAX Score predicts long-term survival worse than EuroSCORE, as shown by a smaller difference between the highest and lowest tertiles. In the stable patient population, the SYNTAX Score lost its predictive ability completely.

 

The outstanding role of the EuroSCORE was confirmed by a multivariable Cox regression analysis adjusted for the relevant baseline characteristics. The EuroSCORE remained as independent predictors of long-term mortality in the entire population (HR per tertile 2.03; 95% CI 1.53–2.69).

 

In conclusion, a combination of clinical and anatomical risk factors may provide the optimal predictive model in patients undergoing multivessel PCI. Furthermore, the ideal combination of clinical and anatomic risk stratification should be conclusive for patients undergoing CABG as well.

 

Ralf Lehmann is an interventional cardiologist at Klinikum der JW Goethe Universität, Frankfurt, Germany.  





Add New Comment

Related Items


Most popular


CE mark for QT Vascular’s Chocolate Heart drug-coated balloon
Thursday, 07 Jul 2016
QT Vascular has received CE mark clearance for the sale and distribution of its Chocolate Heart drug-coated balloon for dilatation of the stenotic portion of coronary arteries for the purpose of ... CE mark for QT Vascular’s Chocolate Heart drug-coated balloon

Versa Capital Management to acquire SynCardia Systems
Wednesday, 06 Jul 2016
SynCardia Systems has entered into an asset purchase agreement with an affiliate of Versa Capital Management to acquire substantially all of the company’s assets and operations, bringing with it the ... Versa Capital Management to acquire SynCardia Systems

AHA warn that some over-the-counter drugs may cause or worsen heart failure
Monday, 18 Jul 2016
Commonly used medications and nutritional supplements may cause or worsen heart failure, according to the first scientific statement from the American Heart Association (AHA) to provide guidance on ... AHA warn that some over-the-counter drugs may cause or worsen heart failure

Features


TAVI durability: A rose by any other name is still a rose
Wednesday, 20 Jul 2016
The data that Dvir presented at EuroPCR, as reported by Cardiovascular News, indicate that there is a significant increase in valve degeneration between five and seven years after a transcatheter ... TAVI durability: A rose by any other name is still a rose

Exploring the borders of TAVI
Monday, 11 Jul 2016
The NOTION 2 trial, which recently enrolled a 64-year-old female with Society of Thoracic Surgeon (STS) score 1.2% as its first patient, is comparing the use of TAVI with the use of surgical aortic ... Exploring the borders of TAVI

Profiles


James Blankenship
Wednesday, 08 Jun 2016
James Blankenship is the 2015–2016 president of SCAI and has been involved with designing and ... James Blankenship

Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions